<- Go Home
Cingulate Inc.
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Market Cap
$13.8M
Volume
1.0M
Cash and Equivalents
$10.0M
EBITDA
-$15.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$10.1M
Profit Margin
N/A
52 Week High
$152.40
52 Week Low
$1.80
Dividend
N/A
Price / Book Value
1.09
Price / Earnings
-0.19
Price / Tangible Book Value
1.09
Enterprise Value
$4.0M
Enterprise Value / EBITDA
-0.26
Operating Income
-$16.2M
Return on Equity
273.82%
Return on Assets
-104.33
Cash and Short Term Investments
$10.0M
Debt
$234.2K
Equity
$12.0M
Revenue
N/A
Unlevered FCF
-$10.0M
Sector
Pharmaceuticals
Category
N/A